$9.160
-0.541 (-5.91%)Zum Schluss
ACOG-News
ACOG-Events
Alpha Cognition Q2 Revenue at $6M, Below Consensus
Reports Q2 revenue $6M, consensus $6.11M. "We are pleased with the continued commercial adoption of ZUNVEYL during the second quarter," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "Our commercial team continues to execute effectively, expanding the prescriber base while driving deeper utilization within existing accounts. We are particularly encouraged by the growth in repeat prescribers, long-term care facility adoption and monthly prescription demand, which we believe reflects increasing clinical confidence in ZUNVEYL. Its differentiated profile and growing real-world utilization provide a strong foundation for continued growth."
Alpha Cognition Inc Trading Halted Due to Volatility Trading Pause
Alpha Cognition Inc trading halted, volatility trading pause
Alpha Cognition Secures European Patent for ZUNVEYL
Alpha Cognition announced that the European Patent Office, EPO, has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer's disease. The patent includes claims directed to the specific crystalline solid form, related pharmaceutical compositions, preparations, methods of manufacture and medical-use claims. The grant further strengthens Alpha Cognition's global intellectual property portfolio and may provide additional patent protection for benzgalantamine's pharmaceutical development and potential commercialization into 2042, subject to applicable patent requirements. "This European patent grant is another important step in our strategy to build broad intellectual property protection around benzgalantamine and ZUNVEYL as a differentiated treatment option for patients with mild-to-moderate Alzheimer's disease," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "By strengthening our IP position in Europe, we are continuing to support the long-term clinical and commercial potential of benzgalantamine."
Alpha Cognition Board Changes, Robert Wills Elected Chairman
Alpha Cognition announced changes to its Board of Directors. Robert Wills has been elected Chairman of the Board, succeeding Len Mertz, who has retired from the Board after years of dedicated service and leadership. Wills has served on Alpha Cognition's Board of Directors since 2025, and currently serves as Chair of the Governance and Nominating Committee and as a member of the Audit Committee.
Alpha Cognition Begins Patient Enrollment in ZUNVEYL RESOLVE Study
Alpha Cognition announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The RESOLVE study is expected to enroll approximately 150 patients across multiple clinical sites and will monitor adverse events, treatment persistence, and discontinuation rates throughout the study. Data generated from RESOLVE is expected to complement findings from previous clinical studies and contribute to the growing body of evidence supporting the use of ZUNVEYL in clinical practice.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.